Ann: Audeo Oncology Board Appointments , page-6

Finally, David U'Prichard

....He served as the Chief Executive Officer of 3-Dimensional Pharmaceuticals, Inc. (“3DP“) from September 1999 to 2003. From 1997 to 1999, he served as the President and Chairman of Research and Development at SmithKline Beecham Limited, where he oversaw the entry of approximately ten compounds into global development, the international registration of the diabetes drug Avandia®, and the entry of four compounds into Phase III trials and six compounds into early clinical trials. Dr. U’Prichard instituted several major restructuring efforts at SmithKline. Prior to this, he worked for ICI/Zeneca from 1986 to 1997, where he served as an Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs, including Seroquel, Accolate, Avandia, and Iressa....continues...

Source: http://investing.businessweek.com/research/stocks/private/person.asp?personId=140809&privcapId=53563013&previousCapId=9098039&previousTitle=Yankee%20Hill%20Capital%20Management,%20LLC